9 completed, 4 unknown, 3 terminated, 2 active not recruiting. 11 Phase 4, 3 Not applicable, 2 Early Phase 1, 2 Phase 1, 2 Phase 3.
Follow moxonidine: new trials by email Literature Review of moxonidine trials Research Report on moxonidine
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Sympathetic Mechanisms in Obesity-Crossover Design Amlodipine, Moxonidine, Placebo - Obesity, Hypertension | Phase 1 / Phase 2 | Recruiting | Vanderbilt University Medical Center | 12 | 2022-05-20 | 2026-02-27 |
| Autonomic Determinants of POTS - Pilot 2 Placebo oral tablet, Moxonidine Pill - Postural Tachycardia Syndrome | Early Phase 1 | Active not recruiting | Vanderbilt University Medical Center | 48 | 2021-08-31 | 2026-03-27 |
| Sympathetic Mechanisms in the Cardiovascular and Metabolic Alterations of Obesity Moxonidine 0.2 MG, Amlodipine 5 MG - Obesity-Associated Insulin Resistance | Phase 1 | Terminated | Italo Biaggioni | 10 | 2021-02-23 | 2025-09-05 |
| Autonomic Determinants of POTS - Pilot1 Moxonidine, Placebo - Postural Tachycardia Syndrome | Early Phase 1 | Active not recruiting | Vanderbilt University Medical Center | 48 | 2019-08-27 | 2026-03-27 |
| Moxonidine + Perindopril in Hypertensive Patients With Metabolic Syndrome perindopril + moxonidine - Arterial Hypertension, Metabolic Syndrome | Phase 4 | Unknown | Sergey V. Nedogoda | 120 | 2019-03-11 | 2019-07-23 |
| Role of Sympathetic Activation in Ischemia Reperfusion Injury Moxonidine 0.2 MG, placebo - Central Sympathetic Nervous System Diseases | Phase 4 | Completed | Royal Perth Hospital | 46 | 2015-07-08 | 2022-09-29 |
| Sympathoinhibition as a Preferred Second Line Treatment of Obesity Related Hypertension Moxonidine 0.4 MG, Amlodipine 5mg - Obesity, Hypertension | Phase 4 | Unknown | Royal Perth Hospital | 120 | 2015-06-24 | 2022-09-29 |
| Comparative Effects of Moxonidine on Bone Metabolism, Vascular and Cellular Aging in Hypertensive Postmenopausal Women Moxonidine, Bisoprolol - Osteopenia, Arterial Hypertension | Not applicable | Completed | National Research Center for Preventive Medicine | 114 | 2015-04-01 | 2021-09-01 |
| Moxonidine for Prevention of Post-ablation AFib Recurrences Moxonidine, Placebo - Atrial Fibrillation | Phase 4 | Completed | Spyridon Deftereos | 150 | 2012-08-01 | 2014-05-06 |
| Alleviating the Metabolic Side Effects of Antipsychotic Medications Moxonidine, Placebo - Schizophrenia | Phase 4 | Withdrawn | Baker Heart and Diabetes Institute | 2012-05-01 | 2019-04-24 | |
| Polycystic Ovary Syndrome - Improving Outcomes Moxonidine, Placebo - Polycystic Ovary Syndrome | Phase 4 | Completed | Baker Heart and Diabetes Institute | 42 | 2012-05-01 | 2018-11-02 |
| The Effect of Moxonidine on Blood Pressure and Regression of Early Target Organ Damage in Young Subjects With Abdominal Obesity and Hypertension Moxonidine, Irbesartan - Abdominal Obesity, Hypertension | Phase 4 | Unknown | Baker Heart and Diabetes Institute | 100 | 2012-01-01 | 2012-02-03 |
| Sympathetic Nervous System Inhibition for the Treatment of Diabetic Kidney Disease Moxonidine, Placebo - Diabetic Nephropathies | Phase 4 | Completed | Baker Heart and Diabetes Institute | 48 | 2011-04-01 | 2023-09-14 |
| Study of the Effect of Moxonidine and Diet on Sympathetic Functions in Young Adults With Obesity Moxonidine (Physiotens), Dietary intervention - Obesity, Overweight | Phase 4 | Unknown | Baker Heart and Diabetes Institute | 77 | 2010-09-01 | 2013-11-05 |
| Treatment of Adiposity Related hypErTension (TARGET) Aliskiren, Moxonidine, Hydrochlorothiazide - Hypertension, Abdominal Obesity | Phase 4 | Completed | UMC Utrecht | 32 | 2010-08-01 | 2012-02-24 |
| Moxonidine Effects on Neuropeptide Y Moxonidine - Obesity, Hypertension | Phase 4 | Completed | Aristotle University Of Thessaloniki | 90 | 2010-01-11 | 2021-12-07 |
| Effects of Intensive Long-Term Vasodilation in Hypertensive Patients With Microvascular Angina Pectoris Lercanidipine, Valsartan, Nicorandil - Microvascular Angina, Hypertension | Not applicable | Terminated | University of Aarhus | 10 | 2007-01-01 | 2009-05-06 |
| Efficacy and Safety of Moxonidine in Indian Patients Moxonidine - Hypertension | Phase 3 | Completed | Solvay Pharmaceuticals | 100 | 2005-07-01 | 2009-01-30 |
| Pathophysiological Mechanisms of Hypertensive LVH:Optimising Regression Bendroflumethiazide 2.5mg OD; Amlodipine 10mg OD, Valsartan 160mg OD; Moxonidine 400mcg OD - Hypertension, Left Ventricular Hypertrophy | Not applicable | Completed | University of Leeds | 42 | 2003-09-01 | 2012-08-16 |
| Moxonidine in Patients Undergoing Vascular Surgery moxonidine - Cardiac Disease, Vascular Surgery | Phase 3 | Terminated | University Hospital, Basel, Switzerland | 141 | 2002-11-01 | 2009-11-10 |
Hypertension (10) · Obesity (5) · Metabolic Syndrome (2) · Obesity, Abdominal (2) · Postural Orthostatic Tachycardia Syndrome (2) · Atrial Fibrillation (1) · Bone Diseases, Metabolic (1) · Depression (1) · Diabetic Nephropathies (1) · Heart Diseases (1) · Hypertrophy, Left Ventricular (1) · Ischemia (1) · Mental Disorders (1) · Microvascular Angina (1) · Osteopetrosis, mild autosomal recessive form (1)
Baker Heart and Diabetes Institute (5) · Vanderbilt University Medical Center (3) · Royal Perth Hospital (2) · Aristotle University Of Thessaloniki (1) · Italo Biaggioni (1) · National Research Center for Preventive Medicine (1) · Sergey V. Nedogoda (1) · Solvay Pharmaceuticals (1) · Spyridon Deftereos (1) · UMC Utrecht (1) · University Hospital, Basel, Switzerland (1) · University of Aarhus (1) · University of Leeds (1)
Australia (7) · United States (4) · Russia (2) · Denmark (1) · Greece (1) · India (1) · Netherlands (1) · Switzerland (1) · United Kingdom (1)
Abdul Khalid (1) · David Barton (1) · Eleni Karlafti, MD, PhD (1) · Gavin Lambert (1) · Gavin Lambert, Dr (1) · Gavin W Lambert, BSc PhD (1) · Italo Biaggioni, MD (1) · John P Greenwood, MBChB, PhD (1) · Kent L Christensen, MD, DrMSc (1) · Markus P Schlaich, MD (1)
PMID 17389264, PMID 17968979, PMID 25147079, PMID 25847478, PMID 28865109, PMID 29085669, PMID 30410448, PMID 30520854, PMID 30548504, PMID 32847570
R01HL142583 (1), R01HL149386 (1), R56HL142583 (1)